Rasonque™: A New Drug for Pancreatic Cancer

The U.S. Food & Drug Administration (FDA) just approved a treatment that doubled survival time for patients with metastatic pancreatic cancer — what does this landmark approval mean for you or a loved one? To get the latest information, host Alisyn Camerota is joined by Dr. Brian Wolpin, a medical oncologist at Dana-Farber Cancer Institute and professor of medicine at Harvard Medical School.Dr. Wolpin breaks down what the FDA's approval of Rasonque™ (daraxonrasib) means for patients, how the drug works differently from chemotherapy, who's eligible to receive it, what side effects look like and how they're managed, and what's next as researchers explore other types of RAS inhibitors, novel combinations, different stages of disease, and more. PancChat is produced in collaboration with Let's Win Pancreatic Cancer and PanCAN.  Thanks to our sponsor, Revolution Medicines.Resources: FDA Approves RASONQUE™ (daraxonrasib) - PanCAN The FDA Approves Rasonque™ (Daraxonrasib) - Let's Win Daraxonrasib: What To Know About Common Side EffectsLet's Win Pancreatic Cancer Pancreatic Cancer Action Network (PanCAN) Let's Win Clinical Trial Finder PanCAN Clinical Trial Finder Let's Win Doctor Finder PanCAN Patient Services